Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.87 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.81 |
| ▸ | TSHR | P16473 | 3/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5280013 | 0.96 | POLB (0.93) | POLBKMT2ATSHRKDM4ESMN1; SMN2 | |
| SCHEMBL5314300 | 0.92 | KMT2A (0.81) | POLBKMT2ATSHRKDM4ESMN1; SMN2 | |
| SCHEMBL10751242 | 0.84 | — | — | |
| SCHEMBL18713004 | 0.83 | POLB (0.70) | POLBKMT2ATSHRKDM4ESMN1; SMN2 | |
| SCHEMBL16439724 | 0.83 | KDM4E (0.95) | POLBKMT2ATSHRKDM4ESMN1; SMN2 | |
| SCHEMBL6962582 | 0.81 | POLB (0.67) | POLBKMT2ATSHRKDM4ESMN1; SMN2 | |
| SCHEMBL9028142 | 0.81 | POLB (0.67) | POLBKMT2ATSHRKDM4ESMN1; SMN2 | |
| SCHEMBL3176249 | 0.81 | KDM4E (1.00) | POLBKMT2ATSHRKDM4ESMN1; SMN2 | |
| SCHEMBL7955480 | 0.79 | POLB (0.56) | POLBKMT2ATSHRKDM4ESMN1; SMN2 | |
| SCHEMBL2422007 | 0.77 | POLB (0.61) | POLBKMT2ATSHRKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3261639-B1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS | VERSEON INT CORPORATION (US) | 2022-08-24 | — | — | EP | claimed |
| US-11165097-B2 | Electrolyte, electrochemical device and electronic device containing the same | NINGDE AMPEREX TECHNOLOGY LIMITED (CN) | 2021-11-02 | — | — | US | disclosed |
| US-20200243905-A1 | ELECTROLYTE, ELECTROCHEMICAL DEVICE AND ELECTRONIC DEVICE CONTAINING THE SAME | NINGDE AMPEREX TECHNOLOGY LIMITED | 2020-07-30 | — | — | US | disclosed |
| CN-106061971-B | Pyrrolidinyl sulfone derivatives and their use as ROR gamma modulators | 百时美施贵宝公司 | 2019-03-12 | — | — | CN | disclosed |
| CN-106061971-B | Pyrrolidinyl sulfone derivatives and their use as ROR gamma modulators | 百时美施贵宝公司 | 2019-03-12 | — | — | CN | disclosed |
| CN-105102449-B | Antiviral compound | 豪夫迈·罗氏有限公司 | 2017-06-13 | — | — | CN | disclosed |
| CN-106061971-A | Pyrrolidinyl sulfone derivatives and their use as ROR gamma modulators | 百时美施贵宝公司 | 2016-10-26 | — | — | CN | disclosed |
| CN-106061971-A | Pyrrolidinyl sulfone derivatives and their use as ROR gamma modulators | 百时美施贵宝公司 | 2016-10-26 | — | — | CN | disclosed |
| US-9458171-B2 | Pyrrolidinyl sulfone RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-04 | — | — | US | disclosed |
| CN-105102449-A | Antiviral compounds | HOFFMANN LA ROCHE | 2015-11-25 | — | — | CN | disclosed |
| US-7851463-B2 | Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | ABBOTT GMBH & CO. KG (DE) | 2010-12-14 | — | — | US | disclosed |
| WO-2010118367-A2 | ANTIVIRAL PYRIMIDINES | PROGENICS PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20090306175-A1 | HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2009-12-10 | — | — | US | disclosed |
| CN-101421234-A | Is suitable for treating p-hydroxytryptamine 5HT6Heterocyclic aryl sulfones of receptor-modulated responsive disorders | ABBOTT GMBH (DE) | 2009-04-29 | — | — | CN | disclosed |
| EP-2029528-A1 | HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2009-03-04 | — | — | EP | disclosed |
| US-20080045493-A1 | Heterocyclic Compounds Suitable For Treating Disorders That Respond To Modulation Of The Dopamine D3 Receptor | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2008-02-21 | — | — | US | disclosed |
| WO-2007118899-A1 | HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2007-10-25 | — | — | WO | disclosed |
| CN-101039904-A | Is suitable for treating dopamine D3Heterocyclic compounds for receptor-modulated responsive disorders | ABBOTT GMBH & CO KG (DE) | 2007-09-19 | — | — | CN | disclosed |
| EP-1814849-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006040182-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306175-A1 | HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | HTR6, HTR1A, HTR5A | POLB 4814/4885KMT2A 1530/4885TSHR 107/4885 |
| US-20080045493-A1 | Heterocyclic Compounds Suitable For Treating Disorders That Respond To Modulation Of The Dopamine D3 Receptor | DRD3, MC3R, CHRNA3 | POLB 4018/4885KMT2A 2936/4885TSHR 38/4885 |
| US-11165097-B2 | Electrolyte, electrochemical device and electronic device containing the same | CA3, SCNN1G, SCN10A | POLB 2163/4885KMT2A 940/4885TSHR 2512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.